Invokana (medicine for treatment of diabetes)

2017: Risk of amputation of extremities

In June, 2017 the American diabetologichesky association (American Diabetes Association, ADA) published results of a research according to which the medicine developed by Johnson & Johnson for treatment of diabetes of Invokana reduces risk of development of heart failure, however also amputations of extremities can become a cause of destruction of bones.

According to ADA, the patients 14% more rare accepting Invokana faced heart attack and a stroke or died of heart diseases in comparison with those who were given placebo — the substance without explicit medicinal properties used as medicine which medical effect is connected with belief of the patient in effectiveness of medicine.

Invokana

Invokana is SGLT-2 inhibitor and is appointed to patients with diabetes of the second type. Medicine helps to bring glucose out of a body naturally. About 6% of $40 billion annual expenses on remedies (data of Bloomberg) fall to the share of SGLT-2.

However at Invokana the serious ghost effect is revealed: use of medicine doubles risk of fractures of extremities and amputation of toes or legs. Such problem met on average at each 6.3 patients from 1000. In total more than 10 thousand people sick with type 2 diabetes participated in a research.

Results of a research are positive for drugs of class SGLT-2 in general as they confirm their advantage regarding reduction of risk of cardiovascular diseases. However the unusual danger of amputation of Invokana does the medicine Jardiance more attractive — the analyst from Sanford C notes. Bernstein & Co. Tim Anderson.

Jardiance caused a big resonance in 2015 when clinical trials showed that this medicine reduces risk of hospitalization at heart failure or death from heart failure at 39% of patients.^[1]

Notes